The global adhesion barrier market size was valued at USD 695.5 million in 2019 and is projected to witness a CAGR of 7.1% during the forecast period. The key drivers of the market are the rising geriatric population coupled with the increasing number of surgical procedures. The rising incidence of invasive surgeries with a high risk of postoperative complications is triggering the growth. However, with the rising risk of post-operation adhesion, the market is still witnessing barriers in terms of accessibility, lack of health education, and lack of awareness about the importance of treatment.
Improvement in healthcare infrastructure and the increasing availability of trauma care centers are expected to drive the growth. Moreover, increasing incidences of sports-related injuries are also contributing to the market growth. According to Stanford Children’s Health, there are approximately 30 million children who participate in some form of sports, and out of this more than 10% have injuries each year. Also, according to the Centers for Disease Control and Prevention (CDC), there were 51.4 million orthopedic procedures performed in the U.S. in 2015. The rising number of orthopedic procedures is expected to have a positive impact on the demand for advanced adhesion barriers.
Increasing incidence of neurological disorders, gynecological disorder, ophthalmic disorder, and cardiac disorder have also contributed in propelling the market growth. According to the British Heart Association, there are 7.4 million people living with circulatory and heart diseases. Heart and circulatory diseases accounted for approximately 27% of all deaths in the U.K. in 2019. Thus, the treatment of these disorders requires surgical interventions at certain times, increasing the demand for adhesion barriers.
Furthermore, rising healthcare expenditure coupled with rising FDA approval for various adhesion barrier products is also adding growth to the market. For instance, in March 2018, the SurgiWrap film adhesion barrier from Keir Surgical received approval from Health Canada for sale in Canada. In addition, favorable reimbursement policies and the rising awareness about various surgical interventions are boosting market growth over the forecast period.
On the basis of product, the adhesion barrier market is segmented into synthetic adhesion barriers and natural adhesion barriers. The synthetic adhesion barrier segment accounted for the largest market size owing to high bioresorbable and biocompatibility properties. Synthetic adhesion barriers are cost-effective, which is expected to increase sales of the segment. Moreover, the dominance of the segment is primarily attributed to the availability of commercial synthetic adhesion barriers. The segment is further divided into hyaluronic acid, regenerated cellulose, polyethylene glycol, and others. The hyaluronic acid segment dominates, owing to its capacity to attract and hold a vast amount of moisture.
The natural adhesion barriers segment also accounted for considerable market share in 2019 and is expected to grow at a lucrative rate during the forecast period. The segment is further divided into collagen and protein, and fibrin. The collagen and protein segment held the largest market share in 2019 owing to its benefits such as durability and safety. The fibrin segment is expected to grow at a rapid pace during the forecast period. The high growth rate of the fibrin segment is primarily attributed to the rising adoption of these products.
Based on the application, the market is segmented into gynecological surgeries, abdominal general surgeries, orthopedic surgeries, cardiovascular surgeries, neurological surgeries, urological surgeries, and others. The cardiovascular surgeries segment is expected to exhibit the fastest CAGR during the forecast period. The high growth rate of the segment is primarily attributed to the increasing incidence of heart-related disease and the rising use of adhesion barriers in cardiovascular surgeries. According to the American Heart Association, heart disease caused almost one in four deaths in the U.S. in 2016.
The gynecological surgeries segment held the largest market share in 2019 and is expected to maintain its dominance during the forecast period. Market dominance is primarily attributed to the rising number of gynecologic laparoscopy procedures. Furthermore, the increasing adoption of gel form and film form in various gynecological procedures including endometriosis surgery, ovarian cystectomy, and ectopic pregnancy is boosting the market growth. Slow adoption of minimally invasive techniques in developing countries is expected to have a positive impact on the adoption of adhesion barriers. Minimally invasive surgeries require expensive equipment such as cameras and robot-assisted devices. The adoption of these devices is expected to be moderate in developing countries because of price-sensitive customers.
Based on formulation, the market is segmented into film/mesh, gel, and liquid. The film/mesh segment held the largest market share in 2019 and is expected to maintain its dominance during the forecast period. The large share of the segment is primarily attributed to its low cost and increasing use of film form adhesion in various surgeries. In addition, many clinical pieces of evidence are supporting the efficiency and safety of these forms of adhesion, thus, adding growth to the market.
The gel segment is expected to grow at the fastest rate during the forecast period. The high growth rate of the segment is primarily attributed to its advantages such as affordability, resorbability, easy application, and safety. Moreover, increasing usage of gels in various surgeries such as tendon, carpal tunnel, and joint or peripheral surgery is expected to expand its applications in upcoming years.
Regionally, the market is segmented into North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. North America dominates the market owing to the presence of major players such as Johnson and Johnson, Baxter International, Integra LifeSciences, Anika Therapeutics, and FzioMed. An increase in the prevalence of orthopedic conditions coupled with high adoption of advanced treatment procedures is anticipated to fuel market growth in the U.S.
The Asia Pacific market is expected to grow at a lucrative rate over the forecast period. The high growth rate in the region is primarily attributed to the rising geriatric population and increasing incidences of cardiac and neurosurgery, which require surgical interventions. Moreover, rising private sector investment in healthcare and rapidly expanding medical tourism is expected to drive the market in the region. Major countries such as India, China, and Japan are expected to contribute maximum growth to the region during the forecast period.
The leading players present in the market are Sanofi S.A.; Becton Dickinson and Company; Baxter International, Inc.; Johnson and Johnson; Anika Therapeutics, Inc.; FzioMed, Inc; Mast Biosurgery, Inc.; Innocoll Holdings PLC; and Atrium Medical Corporation (A part of Getinge Group). Increasing product launches, mergers and acquisitions, partnerships, and technological collaboration are the major strategies adopted by most of these players to maintain their market share. For instance, in January 2018, Ethicon announced the U.S. launch of SURGICEL powder absorbable hemostat, an adjunctive hemostat to control disruptive bleeding.
Report Attribute |
Details |
Market size value in 2020 |
USD 747.6 million |
Revenue forecast in 2027 |
USD 1.2 billion |
Growth Rate |
CAGR of 7.1% from 2020 to 2027 |
Base year for estimation |
2019 |
Historical data |
2016 - 2018 |
Forecast period |
2020 - 2027 |
Quantitative units |
Revenue in USD million and CAGR from 2020 to 2027 |
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segments covered |
Product, formulation, application, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
Country scope |
U.S.; Canada; U.K.; Germany; France; Italy; Spain; Switzerland; Netherland; Greece; Poland; Russia; Japan; China; Australia; India; South Korea; Malaysia; New Zealand; Vietnam; Hongkong; Indonesia; Brazil; Mexico; Argentina; Colombia; Chile; South Africa; Saudi Arabia; Oman; Egypt; UAE |
Key companies profiled |
Sanofi S.A.; Becton Dickinson and Company; Baxter International, Inc.; Johnson and Johnson; Anika Therapeutics, Inc.; FzioMed, Inc; Mast Biosurgery, Inc.; Innocoll Holdings PLC; Atrium Medical Corporation (A part of Getinge Group) |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional, and country levels as well as provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2027. For the purpose of this study, Grand View Research has segmented the global adhesion barrier market report on the basis of product, formulation, application, and region:
Product Outlook (Revenue, USD Million, 2016 - 2027)
Synthetic Adhesion Barriers
Hyaluronic acid
Regenerated cellulose
Polyethylene glycol
Others
Natural Adhesion Barriers
Collagen & Protein
Fibrin
Formulation Outlook (Revenue, USD Million, 2016 - 2027)
Film/Mesh
Gel
Liquid
Application Outlook (Revenue, USD Million, 2016 - 2027)
Gynecological Surgeries
Synthetic Adhesion Barriers
Natural Adhesion Barriers
Abdominal General Surgeries
Synthetic Adhesion Barriers
Natural Adhesion Barriers
Orthopedic Surgeries
Synthetic Adhesion Barriers
Natural Adhesion Barriers
Cardiovascular Surgeries
Synthetic Adhesion Barriers
Natural Adhesion Barriers
Neurological Surgeries
Synthetic Adhesion Barriers
Natural Adhesion Barriers
Urological Surgeries
Synthetic Adhesion Barriers
Natural Adhesion Barriers
Others
Synthetic Adhesion Barriers
Natural Adhesion Barriers
Regional Outlook (Revenue, USD Million, 2016 - 2027)
North America
The U.S.
Canada
Europe
The U.K.
Germany
France
Italy
Spain
Switzerland
Russia
Poland
Netherland
Greece
Asia Pacific
Japan
China
India
Australia
South Korea
Vietnam
New Zealand
Malaysia
Indonesia
Hongkong
Latin America
Brazil
Mexico
Argentina
Colombia
Chile
Middle East & Africa
South Africa
Saudi Arabia
UAE
Oman
Egypt
b. The global adhesion barrier market size was valued at USD 695.5 million in 2019 and is expected to reach USD 747.6 million in 2020.
b. The global adhesion barrier market is projected to grow at a compound annual growth rate of 7.1% from 2020-2027 to reach USD 1.2 billion in 2027.
b. North America dominated the adhesion barrier market with a market share of 47.4% in 2019. This is attributable to the increase in the prevalence of orthopedic conditions coupled with the high adoption of advanced treatment procedures.
b. The leading players present in the market are Sanofi S.A.; Becton Dickinson and Company; Baxter International, Inc.; Johnson and Johnson; Anika Therapeutics, Inc.; FzioMed, Inc; Mast Biosurgery, Inc.; Innocoll Holdings PLC; and Atrium Medical Corporation (A part of Getinge Group).
b. Key factors that are driving the market growth include increasing surgical procedures, improvement in healthcare infrastructure, increasing prevalence of chronic diseases and sports-related injury.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
With Covid-19 infections rising globally, the apprehension regarding a shortage of essential life-saving devices and other essential medical supplies in order to prevent the spread of this pandemic and provide optimum care to the infected also widens. In addition, till a pharmacological treatment is developed, ventilators act as a vital treatment preference for the COVID-19 patients, who may require critical care. Moreover, there is an urgent need for a rapid acceleration in the manufacturing process for a wide range of test-kits (antibody tests, self-administered, and others). The report will account for Covid19 as a key market contributor.
We value your investment and offer free customization with every report to fulfil your exact research needs.